Sentence: Conclusions Everolimus plus mFOLFOX-6 + bevacizumab is tolerable and demonstrated preliminary efficacy for first-line mCRC .
Drug combination annotation:
[{'class': 'POS', 'spans': ['Everolimus', 'bevacizumab', 'mFOLFOX-6'], 'is_context_needed': False}]